159 related articles for article (PubMed ID: 38523737)
1. 17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population.
Govardhan B; Anand VK; Nagaraja Rao P; Balachandran Menon P; Mithun S; Sasikala M; Sowmya TR; Anuradha S; Smita CP; Nageshwar Reddy D; Ravikanth V
J Clin Exp Hepatol; 2024; 14(4):101371. PubMed ID: 38523737
[TBL] [Abstract][Full Text] [Related]
2. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
[TBL] [Abstract][Full Text] [Related]
3. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
[TBL] [Abstract][Full Text] [Related]
4. Association of HSD17B13 and PNPLA3 With Liver Enzymes and Fibrosis in Hispanic/Latino Individuals of Diverse Genetic Ancestries.
Rutledge SM; Soper ER; Ma N; Pejaver V; Friedman SL; Branch AD; Kenny EE; Belbin GM; Abul-Husn NS
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2578-2587.e11. PubMed ID: 36610497
[TBL] [Abstract][Full Text] [Related]
5. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
[TBL] [Abstract][Full Text] [Related]
6. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.
Abul-Husn NS; Cheng X; Li AH; Xin Y; Schurmann C; Stevis P; Liu Y; Kozlitina J; Stender S; Wood GC; Stepanchick AN; Still MD; McCarthy S; O'Dushlaine C; Packer JS; Balasubramanian S; Gosalia N; Esopi D; Kim SY; Mukherjee S; Lopez AE; Fuller ED; Penn J; Chu X; Luo JZ; Mirshahi UL; Carey DJ; Still CD; Feldman MD; Small A; Damrauer SM; Rader DJ; Zambrowicz B; Olson W; Murphy AJ; Borecki IB; Shuldiner AR; Reid JG; Overton JD; Yancopoulos GD; Hobbs HH; Cohen JC; Gottesman O; Teslovich TM; Baras A; Mirshahi T; Gromada J; Dewey FE
N Engl J Med; 2018 Mar; 378(12):1096-1106. PubMed ID: 29562163
[TBL] [Abstract][Full Text] [Related]
7. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
9. Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population.
Chen H; Zhang Y; Guo T; Yang F; Mao Y; Li L; Liu C; Gao H; Jin Y; Che Y; Li Y; Huang J
Liver Int; 2020 Sep; 40(9):2194-2202. PubMed ID: 33151633
[TBL] [Abstract][Full Text] [Related]
10. PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children.
Lee KJ; Moon JS; Lim JG; Huh H; Ahn JE; Kim L; Kim NY; Ko JS
J Gastroenterol Hepatol; 2024 Jun; 39(6):1172-1182. PubMed ID: 38418429
[TBL] [Abstract][Full Text] [Related]
11. Whole-Exome Sequencing Identifies a Variant in Phosphatidylethanolamine N-Methyltransferase Gene to be Associated With Lean-Nonalcoholic Fatty Liver Disease.
Bale G; Vishnubhotla RV; Mitnala S; Sharma M; Padaki RN; Pawar SC; Duvvur RN
J Clin Exp Hepatol; 2019; 9(5):561-568. PubMed ID: 31695245
[TBL] [Abstract][Full Text] [Related]
12. Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease.
Liu WY; Eslam M; Zheng KI; Ma HL; Rios RS; Lv MZ; Li G; Tang LJ; Zhu PW; Wang XD; Byrne CD; Targher G; George J; Zheng MH
J Clin Transl Hepatol; 2021 Apr; 9(2):194-202. PubMed ID: 34007801
[TBL] [Abstract][Full Text] [Related]
13. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
[TBL] [Abstract][Full Text] [Related]
14. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
[TBL] [Abstract][Full Text] [Related]
15. Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.
Hudert CA; Adams LA; Alisi A; Anstee QM; Crudele A; Draijer LG; Furse S; Hengstler JG; Jenkins B; Karnebeek K; Kelly DA; Koot BG; Koulman A; Meierhofer D; Melton PE; Mori TA; Snowden SG; van Mourik I; Vreugdenhil A; Wiegand S; Mann JP;
Hepatol Commun; 2022 Aug; 6(8):1934-1948. PubMed ID: 35411667
[TBL] [Abstract][Full Text] [Related]
16. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
[TBL] [Abstract][Full Text] [Related]
17. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
Gellert-Kristensen H; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
Hepatology; 2020 Jan; 71(1):56-66. PubMed ID: 31155741
[TBL] [Abstract][Full Text] [Related]
18. Pooled genetic analysis in ultrasound measured non-alcoholic fatty liver disease in Indian subjects: A pilot study.
Kanth VV; Sasikala M; Rao PN; Steffie Avanthi U; Rao KR; Nageshwar Reddy D
World J Hepatol; 2014 Jun; 6(6):435-42. PubMed ID: 25018854
[TBL] [Abstract][Full Text] [Related]
19. A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Bayard Q; Gustot T; Deviere J; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Hepatology; 2019 Jul; 70(1):231-240. PubMed ID: 30908678
[TBL] [Abstract][Full Text] [Related]
20. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
Tang S; Zhang J; Mei TT; Zhang WY; Zheng SJ; Yu HB
BMC Gastroenterol; 2021 Dec; 21(1):490. PubMed ID: 34930143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
